Skip to content

Amneal Pharmaceuticals

US · AMRX #1854 by market cap Listed 1970
19.65 -0.65 -3.18%
Live - 5344 symbols - heartbeat 483s ago · 2026-10-08 04:01
Pre-market 19.65 0.00%
After-hours 19.65 0.00%
Overnight 19.76 +0.56%
Market cap
6.28B
P/B
190.78
EPS
0.22
Reader sentiment Are you bullish or bearish on AMRX?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    Goldman Sachs Initiates Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Announces Target Price $19
    Market Newswire · 2026/7/22
  • J.P. Morgan Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $22
    Market Newswire · 2026/8/26
  • Rating change
    Piper Sandler Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $17
    Market Newswire · 2026/5/26
  • J.P. Morgan Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating
    Market Newswire · 2026/9/21
  • Barclays Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Maintains Target Price $20
    Market Newswire · 2026/9/21
  • Rating change
    Goldman Sachs Initiates Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Announces Target Price $17
    Market Newswire · 2026/4/23
  • Rating change
    Barclays Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $16
    Market Newswire · 2026/5/20
  • Rating change
    UBS Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating
    Market Newswire · 2026/6/12
  • Rating change
    Goldman Sachs Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Maintains Target Price $19
    Market Newswire · 2026/7/27
  • Barclays Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $20
    Market Newswire · 2026/9/17
  • Rating change
    Piper Sandler Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Maintains Target Price $17
    Market Newswire · 2026/6/4
  • Rating change
    Goldman Sachs Initiates Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Announces Target Price $21
    Market Newswire · 2026/8/10
  • Rating change
    Truist Financial Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating
    Market Newswire · 2026/4/23
  • Rating change
    UBS Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Announces Target Price $23
    Market Newswire · 2026/7/15
  • Rating change
    Goldman Sachs Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Maintains Target Price $17
    Market Newswire · 2026/5/28
  • Rating change
    Goldman Sachs Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $21
    Market Newswire · 2026/7/31
  • Rating change
    Barclays Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Maintains Target Price $16
    Market Newswire · 2026/6/11
  • Rating change
    Leerink Partners Initiates Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Announces Target Price $23
    Market Newswire · 2026/9/9
  • Rating change
    UBS Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $25
    Market Newswire · 2026/8/3
  • Leerink Partners Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Maintains Target Price $23
    Market Newswire · 2026/9/17

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 04:01:02 · For reference only, not investment advice and not tailored to your situation.